Literature DB >> 10022653

Evaluation by ultrasound of abdominal lymphadenopathy in chronic hepatitis C.

M Soresi1, A Carroccio, V Agate, G D Bonfissuto, C Magliarisi, M Fulco, F Aragona, G Montalto.   

Abstract

OBJECTIVE: Abdominal ultrasound has shown a frequent association between abdominal lymphadenopathy (LA) and chronic liver disease, but contradictory data have been reported on its relationship with the main parameters of hepatic function. The aim of this study was to correlate the prevalence of LA in patients who were chronic hepatitis-anti-hepatitis C virus positive prospectively followed-up over the last 3 years and its relationship with biochemical and histological data.
METHODS: 136 RIBA II confirmed positive patients with ALT levels >2N were included. None of these had been or was at the time of study on interferon treatment. Ultrasound was performed using a Toshiba SSA 240 A apparatus with a 3.75 MHz convex probe; the operator was unaware of the other results. Diagnosis of chronic hepatitis in all cases was made on biopsy specimens; the histological activity index (HAI) score, according to Knodell, and the grading (G) and staging (S) scores, according to Desmet, were also evaluated.
RESULTS: LA was found in 54 out of 136 patients (40%); accordingly, patients were divided into two groups: the LN + ve group included 54 patients (M 33, mean age 48.1+/-11.7 yr) and the LN-ve group included 82 patients (M 69, mean age 45.3+/-11.9 yr). LN + ve patients showed significantly higher serum levels of AST (p < 0.0005), ALT (p < 0.001), gammaGLO (p < 0.05) and gammaGT (p < 0.02) than LN - ve patients. There was a more severe degree of liver disease in LN + ve patients, expressed by the higher HAI (p < 0.002), G (p < 0.002), and S (p < 0.005). The chi2 test for linear association analysis confirmed the trend toward greater histological severity in LN + ve patients (chi2 MH = 10.2; p < 0.002). Logistic regression confirmed the association between the presence of LA and AST (p < 0.02), ALT (p < 0.03), G (p < 0.02), and S (p < 0.02).
CONCLUSION: This study showed a moderate prevalence of LA in chronic hepatitis C, lower than that reported in other studies. LA was associated with serum parameters of cytolysis, and above all, with the severity of histological damage.

Entities:  

Mesh:

Year:  1999        PMID: 10022653     DOI: 10.1111/j.1572-0241.1999.00791.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Clinical significance of perihepatic lymphadenopathy in patients with chronic hepatitis C infection.

Authors:  Shahriar Tavakoli-Tabasi; Sheeba Ninan
Journal:  Dig Dis Sci       Date:  2011-01-23       Impact factor: 3.199

2.  Perihepatic lymphadenopathy and the response to therapy in chronic hepatitis C patients().

Authors:  S Longo; G Cotella; F Carletta; M Catacchio; S Antonaci
Journal:  J Ultrasound       Date:  2010-11-19

3.  Perihepatic nodes detected by point-of-care ultrasound in acute hepatitis and acute-on-chronic liver disease.

Authors:  I Che Feng; Szu Jen Wang; Ming Jen Sheu; Lok-Beng Koay; Ching Yih Lin; Chung Han Ho; Chi Shu Sun; Hsing Tao Kuo
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

4.  Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients.

Authors:  Hiromi Hikita; Hayato Nakagawa; Ryosuke Tateishi; Ryota Masuzaki; Kenichiro Enooku; Haruhiko Yoshida; Masao Omata; Yoko Soroida; Mamiko Sato; Hiroaki Gotoh; Atsushi Suzuki; Tomomi Iwai; Hiromitsu Yokota; Kazuhiko Koike; Yutaka Yatomi; Hitoshi Ikeda
Journal:  J Gastroenterol       Date:  2012-07-12       Impact factor: 7.527

5.  Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion.

Authors:  Yen-Ling Ko; Chi-Shu Sun; Kun-Ming Chung; Yu-Min Lin; I-Che Feng; Ming-Jen Sheu; Lok-Beng Koay; Ching-Yih Lin; Chung-Han Ho; Hsing-Tao Kuo
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.